Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International pediatric relapsed AML treatment study
ISRCTN14207975Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin, liposomal daunorubicin, fludarabine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Hannover Medical School. Primary endpoints: Early treatment response, Event-free survival and 3 more. Started Jun 2013; status: completed.
02
Drugs
gemtuzumab ozogamicinliposomal daunorubicinfludarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN14207975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14207975.